All around the world, acutely ill and injured people seek care every day. Frontline providers manage children and adults with medical, surgical and obstetric emergencies, including injuries and infections, heart attacks and strokes, asthma and acute complications of pregnancy. Prioritising an integrated approach to early recognition and resuscitation reduces the impact of all of these conditions.
restoration and maintenance of circulatory blood volume where volume deficiency has been demonstrated and use of a colloid is appropriate in such physiopathological conditions as liver cirrhosis, trauma, cardio-circulatory insufficiency, or severe burns.
Human Prothrombin Complex
Treatment of bleeding and peri-operative prophylaxis of hemorrhagic accidents due to an acquired deficiency in clotting factors of the prothrombin complex, such as deficiency induced by anti-vitamin K treatment, or in case of overdose in anti-vitamin KK vitamins, when urgent deficit correction is required.
Hemophilia is usually an inherited bleeding disorder in which the blood does not clot properly. This can lead to spontaneous bleeding as well as bleeding following injuries or surgery. Blood contains many proteins called clotting factors that can help to stop bleeding. People with hemophilia have low levels of either factor VIII (8) or factor IX (9). The severity of hemophilia that a person has is determined by the amount of factor in the blood. The lower the amount of the factor, the more likely it is that bleeding will occur which can lead to serious health problems.
Human plasma derived Anti-hemophilic Factor VIII / Factor IX
The preparations produced from human blood plasma contain the original natural factor in concentrated form indicated for patients with hemophilia type A or B
Recombinant Anti-hemophilic Factor VIII – Factor IX
Genetically engineered Anti-hemophilic Factor VIII / IX are proteins artificially generated in cultured animal cells, indicated for patients with hemophilia A or B
Immunodeficiency disorders involve problems with the immune system that impair its ability to mount an appropriate defence. As a result, these are almost always associated with severe infections that persist, recur and/or lead to complications, making these disorders severely debilitating and even fatal.
There are two types of immunodeficiency disorders: primary immunodeficiencies are typically present from birth, are generally hereditary and are relatively rare. Secondary immunodeficiencies generally develop later in life and may result following an infection, as is the case with AIDS following HIV infection.
Autoimmune diseases occur when the immune system attacks the body it is meant to protect. People suffering from autoimmune diseases have a defect that makes them unable to distinguish ‘self’ from ‘non-self’ or ‘foreign’ molecules.
Prophylaxis against certain specific viruses/bacteria transmission.
1) Human Normal Immunoglobulin preparations deriving from human plasma used in the treatment of patients who have no, or very low levels of, antibody production.
Normal Immunoglobulin for intravenous use.
Replacement therapy in:
• Primary immunodeficiency syndromes (PID)
• Secondary immunodeficiencies (SID)
• Primary immune thrombocytopenia (ITP)
• Guillain Barré syndrome
• Kawasaki disease
• Chronic inflammatory demyelinating poliradiculoneuropathy (CIDP)
• Multifocal motor neuropathy (MMN)
2) Hyperimmune/Specific immunoglobulins are preparations that contain a high concentration of antibodies to treat particular viruses or bacteria.
Human anti D immunoglobulin for intramuscular use of human origin.
Prevention of Rh(D) immunisation in Rh(D) negative childbearing age women
- Planned antenatal prophylaxis
- Antenatal prophylaxis following complications of pregnancy including:
- Abortion/threatened abortion, ectopic pregnancy or hydatidiform mole, intrauterine fetal death (IUFD), transplacental haemorrhage (TPH) resulting from ante-partum haemorrhage (APH), amniocentesis, chorionic biopsy, obstetric manipulative procedures e.g. external version, invasive interventions, cordocentesis, blunt abdominal trauma or fetal therapeutic intervention.
- Delivery of a Rh(D) positive (D, Dweak, Dpartial) baby
- Treatment of Rh(D) negative childbearing age women after incompatible transfusions of Rh(D) positive blood or other products containing red blood cells e.g. platelet concentrate.
Human anti hepatite B immunoglobulins for intamuscular or intravenous use from human origin.
– Prevention of hepatitis B virus recurrence after liver transplantation for hepatitis B virus induced liver failure. The concomitant use of adequate virostatic agents should be considered, if appropriate, as a standard in hepatitis B re-infection prophylaxis.
-Immunoprophylaxis of hepatitis B
- In case of accidental exposure in non-immunised subjects (including persons whose vaccination is incomplete or status unknown).
- In haemodialysed patients, until vaccination has become effective.
- In the newborn of a hepatitis B virus carrier-mother.
Human anti tetanus immunoglobulins for intramuscular use from human or animal origin.
- Post-exposure prophylaxis
Immediate prophylaxis after tetanus prone injuries in patients not adequately vaccinated, in patients whose immunisation status is not known with certainty and in patients with severe deficiency in antibody production.
- Therapy of clinically manifest tetanus
Active tetanus vaccination should always be administered in conjunction with tetanus immunoglobulin unless there are contraindications or confirmation of adequate vaccination.
Other specific human immunoglobulins.
Human anti citomegalovirus, anti rabies, anti varicella zoster, Anti Scorpion, Anti Snake
Vaccines are agents that teach the body to recognise and defend itself against infections from harmful pathogens, such as bacteria, viruses and parasites. Vaccines provide a sneak ‘preview’ of a specific pathogen, which stimulates the body’s immune system to prepare itself in the event that infection occurs. Vaccines contain a harmless element of the infectious agent that stimulate the immune system to mount a response, beginning with the production of antibodies. Cells responsive to the vaccine proliferate both in order to manufacture antibodies specific to the provoking agent and also to form ‘memory cells’. Upon encountering the infectious agent a second time, these memory cells are quickly able to deal with the threat by producing sufficient quantities of antibody. Pathogens inside the body are eventually destroyed, thereby thwarting further infection. Several infectious diseases including smallpox, measles, mumps, rubella, diphtheria, tetanus, whooping cough, tuberculosis and polio are no longer a threat in Europe due to the successful application of vaccines.
- Anti tetanus
- Anti hepatitis B
- Anti rabies